Since
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-specific T cells have been found to play essential roles in host immune protection and pathology in patients with
coronavirus disease 2019 (COVID-19), this study focused on the functional validation of
T cell epitopes and the development of
vaccines that induce specific T cell responses. A total of 120 CD8+
T cell epitopes from the E, M, N, S, and RdRp
proteins were functionally validated. Among these, 110, 15, 6, 14, and 12
epitopes were highly homologous with SARS-CoV, OC43, NL63, HKU1, and 229E, respectively; in addition, four
epitopes from the S
protein displayed one
amino acid that was distinct from the current SARS-CoV-2 variants. Then, 31
epitopes restricted by the
HLA-A2 molecule were used to generate
peptide cocktail
vaccines in combination with
Poly(I:C), R848 or
poly (lactic-co-glycolic acid) nanoparticles, and these
vaccines elicited robust and specific CD8+ T cell responses in HLA-A2/DR1 transgenic mice as well as wild-type mice. In contrast to previous research, this study established a modified DC-
peptide-PBL cell coculture system using healthy donor PBMCs to validate the in silico predicted
epitopes, provided an
epitope library restricted by nine of the most prevalent
HLA-A allotypes covering broad Asian populations, and identified the
HLA-A restrictions of these validated
epitopes using competitive
peptide binding experiments with HMy2.CIR cell lines expressing the indicated
HLA-A allotype, which initially confirmed the in vivo feasibility of 9- or 10-mer
peptide cocktail
vaccines against SARS-CoV-2. These data will facilitate the design and development of
vaccines that induce
antiviral CD8+ T cell responses in
COVID-19 patients.